Universal CAR 2.0 to Overcome Current Limitations in CAR Therapy

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 Jul 4

PMID 38962014

Authors

Lara Sophie Schlegel

Coralie Werbrouck

Michael Boettcher

Patrick Schlegel

Affiliations

Soon will be listed here.

Abstract

Chimeric antigen receptor (CAR) T cell therapy has effectively complemented the treatment of advanced relapsed and refractory hematological cancers. The remarkable achievements of CD19- and BCMA-CAR T therapies have raised high expectations within the fields of hematology and oncology. These groundbreaking successes are propelling a collective aspiration to extend the reach of CAR therapies beyond B-lineage malignancies. Advanced CAR technologies have created a momentum to surmount the limitations of conventional CAR concepts. Most importantly, innovations that enable combinatorial targeting to address target antigen heterogeneity, using versatile adapter CAR concepts in conjunction with recent transformative next-generation CAR design, offer the promise to overcome both the bottleneck associated with CAR manufacturing and patient-individualized treatment regimens. In this comprehensive review, we delineate the fundamental prerequisites, navigate through pivotal challenges, and elucidate strategic approaches, all aimed at paving the way for the future establishment of multitargeted immunotherapies using universal CAR technologies.

Citing Articles

"Attack!" Cellular Therapies to Attack Pathogens and Tumors.

Eiz-Vesper B, Bonig H Transfus Med Hemother. 2025; 52(1):1-4.

PMID: 39944410 PMC: 11813275. DOI: 10.1159/000543415.

Logic-gated and contextual control of immunotherapy for solid tumors: contrasting multi-specific T cell engagers and CAR-T cell therapies.

Nolan-Stevaux O, Smith R Front Immunol. 2024; 15:1490911.

PMID: 39606234 PMC: 11599190. DOI: 10.3389/fimmu.2024.1490911.

References

Kueberuwa G, Kalaitsidou M, Cheadle E, Hawkins R, Gilham D . CD19 CAR T Cells Expressing IL-12 Eradicate Lymphoma in Fully Lymphoreplete Mice through Induction of Host Immunity. Mol Ther Oncolytics. 2018; 8:41-51. PMC: 5772011. DOI: 10.1016/j.omto.2017.12.003. View

Leen A, Bollard C, Mendizabal A, Shpall E, Szabolcs P, Antin J . Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood. 2013; 121(26):5113-23. PMC: 3695359. DOI: 10.1182/blood-2013-02-486324. View

Sotillo E, Barrett D, Black K, Bagashev A, Oldridge D, Wu G . Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. Cancer Discov. 2015; 5(12):1282-95. PMC: 4670800. DOI: 10.1158/2159-8290.CD-15-1020. View

Minutolo N, Sharma P, Poussin M, Shaw L, Brown D, Hollander E . Quantitative Control of Gene-Engineered T-Cell Activity through the Covalent Attachment of Targeting Ligands to a Universal Immune Receptor. J Am Chem Soc. 2020; 142(14):6554-6568. PMC: 7306176. DOI: 10.1021/jacs.9b11622. View

Ukrainskaya V, Molostova O, Shelikhova L, Pershin D, Kulakovskaya E, Volkov D . Haploidentical donor-derived memory CAR T cells: first in human experience and in vitro correlative study. Blood Adv. 2022; 6(19):5582-5588. PMC: 9577623. DOI: 10.1182/bloodadvances.2021006262. View

Maude S, Laetsch T, Buechner J, Rives S, Boyer M, Bittencourt H . Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):439-448. PMC: 5996391. DOI: 10.1056/NEJMoa1709866. View

Tamada K, Geng D, Sakoda Y, Bansal N, Srivastava R, Li Z . Redirecting gene-modified T cells toward various cancer types using tagged antibodies. Clin Cancer Res. 2012; 18(23):6436-45. DOI: 10.1158/1078-0432.CCR-12-1449. View

Fu Q, Chen N, Ge C, Li R, Li Z, Zeng B . Prognostic value of tumor-infiltrating lymphocytes in melanoma: a systematic review and meta-analysis. Oncoimmunology. 2019; 8(7):1593806. PMC: 6527267. DOI: 10.1080/2162402X.2019.1593806. View

Yang Z, Grote D, Xiu B, Ziesmer S, Price-Troska T, Hodge L . TGF-β upregulates CD70 expression and induces exhaustion of effector memory T cells in B-cell non-Hodgkin's lymphoma. Leukemia. 2014; 28(9):1872-84. PMC: 4145058. DOI: 10.1038/leu.2014.84. View

10.

Glienke W, Dragon A, Zimmermann K, Martyniszyn-Eiben A, Mertens M, Abken H . GMP-Compliant Manufacturing of TRUCKs: CAR T Cells targeting GD and Releasing Inducible IL-18. Front Immunol. 2022; 13:839783. PMC: 8988144. DOI: 10.3389/fimmu.2022.839783. View

11.

Zhang E, Yang P, Gu J, Wu H, Chi X, Liu C . Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy. J Hematol Oncol. 2018; 11(1):102. PMC: 6090669. DOI: 10.1186/s13045-018-0646-9. View

12.

Zhang C, Wang Z, Yang Z, Wang M, Li S, Li Y . Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA Metastatic Colorectal Cancers. Mol Ther. 2017; 25(5):1248-1258. PMC: 5417843. DOI: 10.1016/j.ymthe.2017.03.010. View

13.

Watanabe N, Mo F, McKenna M . Impact of Manufacturing Procedures on CAR T Cell Functionality. Front Immunol. 2022; 13:876339. PMC: 9043864. DOI: 10.3389/fimmu.2022.876339. View

14.

Barber D, Wherry E, Masopust D, Zhu B, Allison J, Sharpe A . Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2005; 439(7077):682-7. DOI: 10.1038/nature04444. View

15.

Fischer J, Paret C, El Malki K, Alt F, Wingerter A, Neu M . CD19 Isoforms Enabling Resistance to CART-19 Immunotherapy Are Expressed in B-ALL Patients at Initial Diagnosis. J Immunother. 2017; 40(5):187-195. PMC: 5424577. DOI: 10.1097/CJI.0000000000000169. View

16.

Schmidt M, Thurber G, Wittrup K . Kinetics of anti-carcinoembryonic antigen antibody internalization: effects of affinity, bivalency, and stability. Cancer Immunol Immunother. 2008; 57(12):1879-90. PMC: 2840397. DOI: 10.1007/s00262-008-0518-1. View

17.

Giri S, Bal S, Godby K, Ravi G, Clark D, Ubersax C . Real-world applicability of commercial chimeric antigen receptor T-cell therapy among older adults with relapsed and/or refractory multiple myeloma. Am J Hematol. 2022; 97(4):E153-E155. DOI: 10.1002/ajh.26472. View

18.

Goodman D, Azimi C, Kearns K, Talbot A, Garakani K, Garcia J . Pooled screening of CAR T cells identifies diverse immune signaling domains for next-generation immunotherapies. Sci Transl Med. 2022; 14(670):eabm1463. PMC: 9939256. DOI: 10.1126/scitranslmed.abm1463. View

19.

Frey N, Gill S, Hexner E, Schuster S, Nasta S, Loren A . Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia. J Clin Oncol. 2020; 38(25):2862-2871. PMC: 8265376. DOI: 10.1200/JCO.19.03237. View

20.

Cichocki F, van der Stegen S, Miller J . Engineered and banked iPSCs for advanced NK- and T-cell immunotherapies. Blood. 2022; 141(8):846-855. PMC: 10023718. DOI: 10.1182/blood.2022016205. View